# Otitopic Static Website

<p style="font-size: 16px"> Otitopic, Inc., founded in 2012, is a privately funded drug development company with a track record of success in biopharmaceutical product development. Otitopic has changed the route of administration of an approved reference listed drug product and intends to file a 505(b)(2) NDA for sale and marketing in the U.S. OTI-0726 is intended to reduce the risk of vascular mortality in patients with suspected acute myocardial infarction (MI).</p>

